ConductScience.org, home

Comparison · NCT06291831-e23f443f

Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Intensive Care Unit (ICU) Admission for Any Cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Intensive Care Unit (ICU) Admission for Any Cause. Trial comparisons, record NCT06291831-e23f443f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06291831-e23f443f

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.00150.0005090.00439wilson
Risk in group 20.0009940.0001750.00561wilson
Risk difference, group 1 minus group 20.000502-0.004220.00351newcombe hybrid score
Risk ratio, group 1 over group 21.510.15714.5log
Odds ratio, group 1 over group 21.510.15614.5log
Number needed to treat, for one more participant with the outcome on Treated With Paxlovid than on Not Treated With Paxlovid1,990from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Treated With Paxlovid
Participants who were diagnosed with COVID-19 and accepted offer for treatment with Paxlovid (nirmatrelvir, ritonavir) treatment in real world setting. No intervention was administered under this study.
32,005OG000
Group 2Not Treated With PaxlovidParticipants who were diagnosed with COVID-19 and declined offer for treatment with Paxlovid (nirmatrelvir, ritonavir) treatment. This reporting arm served as control group.11,006OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Intensive Care Unit (ICU) Admission for Any Cause
Description
Time frame
Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study
Population
Analysis population included all eligible participants whose data were included and observed in this study.

Source ClinicalTrials.gov

Trial

Title
A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.
NCT number
NCT06291831
Phases
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir, Controls
Lead sponsor
Pfizer
Results first posted
2025-08-19

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT06291831-e23f443f